@article{4df68016ae5f4ffc8bee8304a6677f8d,
title = "Sequencing therapies in oncogene-driven non-small-cell lung cancer: How to get the best mileage?",
author = "Vineeth Sukrithan and Rose Snyder and Haiying Cheng and Bal{\'a}zs Halmos",
note = "Funding Information: B Halmos reports grants and personal fees from AstraZeneca, grants from Mirati, grants and personal fees from Boehringer In-gelheim, personal fees from Genentech, grants and personal fees from Eli Lilly, grants and personal fees from Merck, grants and personal fees from BMS, grants and personal fees from Novartis, grants and personal fees from Pfizer, personal fees from Spectrum, personal fees from Ignyta, grants and personal fees from Takeda, personal fees from Foundation Medicine, grants and personal fees from Guardant Health, outside the submitted work. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.",
year = "2019",
doi = "10.2217/fon-2019-0103",
language = "English (US)",
volume = "15",
pages = "2899--2904",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Taylor and Francis Ltd.",
number = "25",
}
SDG 3 Good Health and Well-being